Life Science and Biopharma vertical focusses on disruptive innovations in the field such as precision medicine, genomics, next-generation sequencing, molecular biology, and in-vitro diagnostics among other new-age treatment therapies. This vertical keeps track of rapid growth of gene therapy, cell therapy, biologics, and next-generation vaccines that are driving the market, as well as on improves visibility on emerging trends, regulations, and competitor landscape that promises to address key challenges in the healthcare industry.
The recombinant cell culture supplements market analysis by BIS Research projects the market to grow at a significant CAGR of 12.93% during the forecast period, 2019-2029. The recombinant cell culture supplements market generated $258.8 million revenue in 2018, in terms of value.
The global human microbiome modulators market has been witnessing a steady annual growth rate of approximately 6.08% in past three years (2015-2017), and the market is expected to continue to grow with a double digit CAGR of 16.29% during the forecast period, 2018-2023.
The global enzymes market was valued $6.57 billion in 2017 and is anticipated to reach $10.63 billion by 2025. The growing demand for enzymes in various industries is the major reason for the growth of this market.
The global biosensors market was valued $1.46 billion in 2017. With the growing prominence of point of care testing services, aided by rising geriatric population and rapid incorporation of biosensing technologies in non-medical applications, the global biosensors market is anticipated to witness an impressive double-digit growth rate.
The regenerative medicines market generated $17.03 billion revenue in 2016. The North America regenerative medicines market currently holds 39% percent of the global regenerative medicines market. Technological innovations across the various segments of the regenerative medicine have propelled growth in the recent past in the region.
The global women’s health market was estimated at $30.88 billion in 2016 and is estimated to grow over $42.12 billion by 2023. The rising geriatric population among women leading to higher incidence rate of menopause and related diseases is the major factor driving the growth of the market.
The pharmaceuticals and biotechnology as well as food and beverages industry are the largest end users in industrial microbiology market due to increasing drug development, growing demand of pathogen testing in food products and increase in significance of industrial food and safety.
The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.
The global biologics market generated a revenue of $238.8 billion in 2016. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.
The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023. Due to side effects of drugs on long term use, patients who fail to respond to medication & the availability of new technology, the device market is set to grow in future.
IVD is expected to increase to $76 billion by 2023 and increase its influence over healthcare spending globally. The category’s rate of growth is accelerating due to a number of key macro forces, such as demand from emerging economies, aging population, evolving clinician attitudes, and a much needed push towards theranostics and personalized medicine.